REGLAN® (Metoclopramide)

In February of 2009, the FDA announced that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a black boxed warning to their drug labels because its chronic use has been linked to a very serious, rarely reversible disorder called tardive dyskinesia. Metoclopramide is a component in REGLAN® Tablets, REGLAN® Oral Disintegrating Tablets, and REGLAN® Injection, as well as Metocloparmide Oral Solution. More than two million Americans use these products.

WHAT IS TARDIVE DYSKINESIA?

Tardive dyskinesia is a motor disorder characterized by involuntary and repetitive movement, including lip smacking, grimacing, tongue protrusion, rapid eye movements, rapid blinking, puckering or pursing of the lips, impaired movements of the fingers, as well as rapid movement the extremities, arms, legs, hips and trunk. These symptoms can range from mild to very severe and are rarely reversible. There is no known treatment.

If you or a loved one has experienced the symptoms of tardive dyskinesia as a result of taking REGLAN® (metoclopramide), you may be entitled to compensation. Contact the offices of Morris, Sullivan & Lemkul, LLP today about a free, confidential REGLAN® case evaluation.